Why the study?
Little was known about the association between the CHA2DS2-VASc score and postoperative outcomes in patients with AF.
Does a higher CHA2DS2-VASc score predict postoperative complications and mortality in AF patients undergoing noncardiac surgery?
Does a higher CHA2DS2-VASc score predict postoperative complications and mortality in AF patients undergoing noncardiac surgery?
The CHA2DS2-VASc score is highly associated with postoperative septicemia, intensive care admission, and 30-day mortality in AF patients undergoing noncardiac surgery, suggesting its utility in perioperative risk evaluation.
Higher CHA2DS2-VASc scores signal elevated postoperative risks in AF; hypothesis-generating for perioperative stratification, prospective validation required.
BACKGROUND: Little was know about the association between the CHA2DS2-VASc score and postoperative outcomes. Our purpose is to evaluate the effects of CHA2DS2-VASc score on the perioperative outcomes in patients with atrial fibrillation (AF). METHODS: We identified 47,402 patients with AF over the age of 20 years who underwent noncardiac surgeries between 2008 and 2013 from claims data of the National Health Insurance in Taiwan. The CHA2DS2-VASc score was used to evaluate postoperative complications, mortality and the consumption of medical resources by calculating adjusted odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: Compared with patients with a CHA2DS2-VASc score of 0, patients with scores ≥ 5 had an increased risk of postoperative septicemia (OR 2.76, 95% CI 2.00-3.80), intensive care (OR 2.55, 95% CI 2.12-3.06), and mortality (OR 2.04, 95% CI 1.14-3.64). There was a significant positive correlation between risk of postoperative complication and the CHA2DS2-VASc score (P < 0.0001). CONCLUSION: The CHA2DS2-VASc score was highly associated with postoperative septicemia, intensive care, and 30-day mortality among AF patients. Cardiologists and surgical care teams may consider using the CHA2DS2-VASc score to evaluate perioperative outcome risks in patients with AF.
No takes yet. Share an insight, caveat, or question.
Sung et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: